XAGE3

Across TCGA pan-cancer cohorts, XAGE3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XAGE3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher XAGE3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XAGE3 expression acts as an unfavorable survival marker.

STAD, LUSC, and SKCM are the cancer types where XAGE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	33	view →
LUSC	OS	Median	All	0.200	0.676	.007	9	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

XAGE3–STAD (OS)

Open the STAD breakdown →